

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL RESULTS OF TY-302, TY-2699a AND TY-0540 ACCEPTED FOR POSTER PRESENTATION AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Phase I clinical trial results for three internally-developed clinical products of the Company, namely TY-302, TY-2699a, and TY-0540, have been officially accepted for poster presentation at the 2025 European Society for Medical Oncology (ESMO) Congress. Relevant detailed data from the trials will be presented during the conference and simultaneously published in the ESMO official journal, *Annals of Oncology*.

About CDK4/6 Inhibitor TY-302

TY-302 is a potent and selective oral cyclin-dependent kinase (“**CDK**”) 4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. By targeting CDK4/6, a key cell cycle regulator, TY-302 suppresses the phosphorylation of the retinoblastoma protein (“**Rb**”), preventing proliferation of cancer cells. TY-302 was modified by H/D exchange of palbociclib, the best-selling CDK4/6 inhibitor in the world. Preclinical studies show that it has a lower incidence of gastrointestinal side effects and a more manageable haematological toxicity profile. Phase I clinical data show that this drug, when combined with toremifene, demonstrates significant efficacy and favourable safety in treating the late-line HR+/HER2 – advanced breast cancer patients. Data accepted for presentation comes from a Phase I multicenter combination therapy clinical trial (NCT04433494), with subsequent clinical studies ongoing.

About CDK7 Inhibitor TY-2699a

TY-2699a is a selective CDK7 inhibitor designed for the treatment of advanced/metastatic solid tumors. Preclinical studies have confirmed that the drug can selectively inhibit cancer cell growth at doses to which normal cells are insensitive. Preliminary clinical data suggests that TY-2699a offers both excellent safety and initial efficacy at comparable doses to other drugs in the same category. The data accepted for presentation comes from a Phase I multicenter monotherapy dose-escalation clinical trial (NCT05866692), and a monotherapy extension study targeting triple-negative breast cancer (TNBC) is currently underway.

About CDK2/4 Inhibitor TY-0540

TY-0540 is a selective CDK2 inhibitor intended for the treatment of solid tumors such as breast cancer, ovarian cancer, and prostate cancer. As a CDK2/4 inhibitor independently developed by the Company, TY-0540 demonstrates potent inhibition of key targets, including CDK2/CycA2 and CDK2/CycE1, as well as the activity of other related targets including CDK4/CycD1 and CDK6/CycD3. Preclinical and clinical studies show that the drug exhibits significant inhibitory effects and favorable safety profiles in multiple solid tumors, including breast cancer (such as palbociclib-resistant models) and ovarian cancer. Data accepted for presentation comes from a Phase I multicenter open-label clinical trial (NCT06246071), with ongoing Phase Ib/II studies.

About ESMO

Founded in 1975, the European Society for Medical Oncology (ESMO) is a leading academic organization in the field of oncology worldwide. The ESMO Congress 2025 will be held from October 17 to 21 in Berlin, Germany, and is expected to attract over 30,000 oncology professionals. The acceptance of the three drug studies at the Congress reflects high international academic recognition of the Company's innovative pharmaceutical R&D direction.

The Company does not guarantee the successful development, marketing and/or commercialization of TY-302, TY-2699a, or TY-0540. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 24, 2025

As of the date of this announcement, the Board comprises Dr. WU Yusheng as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Dr. MENG Xiaoying, Mr. HE Chao, and Dr. ZHU Xiangyang as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing, and Dr. SHEN Xiuhua as independent non-executive Directors.